Tesofensine Research

Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease.

Astrup A, Meier DH, Mikkelsen BO, Villumsen JS, Larsen TM · Obesity (Silver Spring) (2008)

Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease.

Lehr T, Staab A, Tillmann C, Trommeshauser D, Raschig A, Schaefer HG · Br J Clin Pharmacol (2007)

A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam.

Lehr T, Staab A, Tillmann C, Trommeshauser D, Schaefer HG, Kloft C · Clin Pharmacokinet (2009)

[The effect of tesofensine on body weight and body composition in obese subjects--secondary publication].

Nielsen AL, Larsen TM, Madsbad S, Breum L, Jensen TJ, Kroustrup JP · Ugeskr Laeger (2009)

Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study.

Rascol O, Poewe W, Lees A, Aristin M, Salin L, Juhel N · Arch Neurol (2008)

The effect of tesofensine on appetite sensations.

Gilbert JA, Gasteyger C, Raben A, Meier DH, Astrup A, Sjödin A · Obesity (Silver Spring) (2012)

The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men.

Sjödin A, Gasteyger C, Nielsen AL, Raben A, Mikkelsen JD, Jensen JK · Int J Obes (Lond) (2010)

Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users.

Schoedel KA, Meier D, Chakraborty B, Manniche PM, Sellers EM · Clin Pharmacol Ther (2010)

Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.

Lehr T, Staab A, Trommeshauser D, Schaefer HG, Kloft C · AAPS J (2010)

Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.

Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM · Lancet (2008)

Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease.

Hauser RA, Salin L, Juhel N, Konyago VL · Mov Disord (2007)

Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.

Bara-Jimenez W, Dimitrova T, Sherzai A, Favit A, Mouradian MM, Chase TN · Mov Disord (2004)

Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity.

Huynh K, Klose M, Krogsgaard K, Drejer J, Byberg S, Madsbad S · Eur J Endocrinol (2022)

Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons.

In plain English: Tesofensine inhibited a subset of LH GABAergic neurons, reducing their ability to promote feeding behavior... and blocked the body weight rebound that often occurs after weight loss.

Perez CI, Luis-Islas J, Lopez A, Diaz X, Molina O, Arroyo B, Moreno MG, Lievana EG, Fonseca E, Castañeda-Hernández G, Gutierrez R. · PLoS One (2024)

Serotonergic anti-obesity agents: past experience and future prospects.

In plain English: The monoaminergic re-uptake inhibitor tesofensine has also been shown to produce impressive weight loss in smaller-scale clinical studies... behavioural specificity and psychological side effects remain an issue.

Halford JC, Boyland EJ, Lawton CL, Blundell JE, Harrold JA. · Drugs (2011)

Expression of concern — effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.

In plain English: Expression of concern for the 2008 TIPO-1 tesofensine trial (Lancet 2008;372:1906-1913).

The Lancet Editors. · Lancet (2013)